Skip to Content

Clinuvel Pharmaceuticals Ltd CUV

Rating as of

Morningstar’s Analysis

Valuation
Currency in AUD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Clinuvel Pharmaceuticals Ltd is an Australia-based biopharmaceutical company. It is engaged in developing drugs for the treatment of genetic and vascular disorders. Its principal compound, SCENESSE is a drug for erythropoietic protoporphyria. Its pioneering work aims at preventing the symptoms of skin diseases related to exposure to harmful UV radiation and at repigmentation of the skin due to several depigmentation disorders. Geographically, it derives a majority of revenue from Europe and the USA.

Contact
535 Bourke Street, Level 11
Melbourne, VIC, 3000, Australia
T +61 396604900
Sector Healthcare
Industry Biotechnology
Most Recent Earnings
Fiscal Year End Jun 30, 2022
Stock Type
Employees 16